Literature DB >> 24089038

Progressive changes in chromatin structure and DNA damage response signals in bone marrow and peripheral blood during myelomagenesis.

M Gkotzamanidou1, E Terpos2, C Bamia3, S A Kyrtopoulos4, P P Sfikakis5, M A Dimopoulos2, V L Souliotis4.   

Abstract

The molecular pathways implicated in multiple myeloma (MM) development are rather unknown. We studied epigenetic and DNA damage response (DDR) signals at selected model loci (N-ras, p53, d-globin) in bone marrow plasma cells and peripheral blood mononuclear cells (PBMCs) from patients with monoclonal gammopathy of undetermined significance (MGUS; n=20), smoldering/asymptomatic MM (SMM; n=29) and MM (n=18), as well as in healthy control-derived PBMCs (n=20). In both tissues analyzed, a progressive, significant increase in the looseness of local chromatin structure, gene expression levels and DNA repair efficiency from MGUS to SMM and finally to MM was observed (all P<0.002). Following ex vivo treatment with melphalan, a gradual suppression of the apoptotic pathway occurred in samples collected at different stages of myelomagenesis, with the severity and duration of the inhibition of RNA synthesis, p53 phosphorylation at serine15 and induction of apoptosis being higher in MGUS than SMM and lowest in MM patients (all P<0.0103). Interestingly, for all endpoints analyzed, a strong correlation between plasma cells and corresponding PBMCs was observed (all P<0.0003). We conclude that progressive changes in chromatin structure, transcriptional activity and DDR pathways during myelomagenesis occur in malignant plasma cells and that these changes are also reflected in PBMCs.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24089038     DOI: 10.1038/leu.2013.284

Source DB:  PubMed          Journal:  Leukemia        ISSN: 0887-6924            Impact factor:   11.528


  49 in total

Review 1.  Many multiple myelomas: making more of the molecular mayhem.

Authors:  Marta Chesi; P Leif Bergsagel
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2011

Review 2.  Homologous repair of DNA damage and tumorigenesis: the BRCA connection.

Authors:  Maria Jasin
Journal:  Oncogene       Date:  2002-12-16       Impact factor: 9.867

Review 3.  Genomics in multiple myeloma.

Authors:  Nikhil C Munshi; Hervé Avet-Loiseau
Journal:  Clin Cancer Res       Date:  2011-03-15       Impact factor: 12.531

4.  Evidence for ongoing DNA damage in multiple myeloma cells as revealed by constitutive phosphorylation of H2AX.

Authors:  D K Walters; X Wu; R C Tschumper; B K Arendt; P M Huddleston; K J Henderson; A Dispenzieri; D F Jelinek
Journal:  Leukemia       Date:  2011-05-13       Impact factor: 11.528

Review 5.  Pathogenesis of myeloma.

Authors:  Kenneth C Anderson; Ruben D Carrasco
Journal:  Annu Rev Pathol       Date:  2011       Impact factor: 23.472

Review 6.  Autologous stem cell transplantation and multiple myeloma cancer stem cells.

Authors:  William Matsui; Ivan Borrello; Constantine Mitsiades
Journal:  Biol Blood Marrow Transplant       Date:  2012-01       Impact factor: 5.742

7.  DNA mismatch repair pathway defects in the pathogenesis and evolution of myeloma.

Authors:  Mark R Velangi; Elizabeth C Matheson; Gareth J Morgan; Graham H Jackson; Penelope R Taylor; Andrew G Hall; Julie A E Irving
Journal:  Carcinogenesis       Date:  2004-05-13       Impact factor: 4.944

8.  Histone H2AX phosphorylation as a molecular pharmacological marker for DNA interstrand crosslink cancer chemotherapy.

Authors:  P H Clingen; J Y-H Wu; J Miller; N Mistry; F Chin; P Wynne; K M Prise; J A Hartley
Journal:  Biochem Pharmacol       Date:  2008-04-16       Impact factor: 5.858

9.  Telomere dysfunction: a potential cancer predisposition factor.

Authors:  Xifeng Wu; Christopher I Amos; Yong Zhu; Hua Zhao; Barton H Grossman; Jerry W Shay; Sherry Luo; Waun Ki Hong; Margaret R Spitz
Journal:  J Natl Cancer Inst       Date:  2003-08-20       Impact factor: 13.506

10.  Genetics and cytogenetics of multiple myeloma: a workshop report.

Authors:  Rafael Fonseca; Bart Barlogie; Regis Bataille; Christian Bastard; P Leif Bergsagel; Marta Chesi; Faith E Davies; Johannes Drach; Philip R Greipp; Ilan R Kirsch; W Michael Kuehl; Jesus M Hernandez; Stephane Minvielle; Linda M Pilarski; John D Shaughnessy; A Keith Stewart; Herve Avet-Loiseau
Journal:  Cancer Res       Date:  2004-02-15       Impact factor: 12.701

View more
  6 in total

1.  Associations of High-Dose Melphalan Pharmacokinetics and Outcomes in the Setting of a Randomized Cryotherapy Trial.

Authors:  Y K Cho; D W Sborov; M Lamprecht; J Li; J Wang; E M Hade; Y Gao; K Tackett; N Williams; D M Benson; Y A Efebera; A E Rosko; S M Devine; M Poi; C C Hofmeister; M A Phelps
Journal:  Clin Pharmacol Ther       Date:  2017-05-26       Impact factor: 6.875

2.  DNA repair of myeloma plasma cells correlates with clinical outcome: the effect of the nonhomologous end-joining inhibitor SCR7.

Authors:  Maria Gkotzamanidou; Evangelos Terpos; Christina Bamia; Nikhil C Munshi; Meletios A Dimopoulos; Vassilis L Souliotis
Journal:  Blood       Date:  2016-07-21       Impact factor: 22.113

Review 3.  Altered primary chromatin structures and their implications in cancer development.

Authors:  Angelo Ferraro
Journal:  Cell Oncol (Dordr)       Date:  2016-03-23       Impact factor: 6.730

4.  Chromatin structure, transcriptional activity and DNA repair efficiency affect the outcome of chemotherapy in multiple myeloma.

Authors:  M Gkotzamanidou; P P Sfikakis; S A Kyrtopoulos; C Bamia; M A Dimopoulos; V L Souliotis
Journal:  Br J Cancer       Date:  2014-07-22       Impact factor: 7.640

5.  Defective DNA repair and chromatin organization in patients with quiescent systemic lupus erythematosus.

Authors:  Vassilis L Souliotis; Konstantinos Vougas; Vassilis G Gorgoulis; Petros P Sfikakis
Journal:  Arthritis Res Ther       Date:  2016-08-04       Impact factor: 5.156

6.  Pharmacokinetic-Pharmacodynamic Model of Neutropenia in Patients With Myeloma Receiving High-Dose Melphalan for Autologous Stem Cell Transplant.

Authors:  Yu Kyoung Cho; Donald J Irby; Junan Li; Douglas W Sborov; Diane R Mould; Mohamed Badawi; Anees Dauki; Misty Lamprecht; Ashley E Rosko; Soledad Fernandez; Erinn M Hade; Craig C Hofmeister; Ming Poi; Mitch A Phelps
Journal:  CPT Pharmacometrics Syst Pharmacol       Date:  2018-10-20
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.